BR0317104A - Composições farmacêuticas dispersáveis - Google Patents

Composições farmacêuticas dispersáveis

Info

Publication number
BR0317104A
BR0317104A BR0317104-3A BR0317104A BR0317104A BR 0317104 A BR0317104 A BR 0317104A BR 0317104 A BR0317104 A BR 0317104A BR 0317104 A BR0317104 A BR 0317104A
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
prevention
treatment
insoluble
administration
Prior art date
Application number
BR0317104-3A
Other languages
English (en)
Other versions
BR0317104B1 (pt
Inventor
Nancy J Britten
Niki A Waldron
John W Burns
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of BR0317104A publication Critical patent/BR0317104A/pt
Publication of BR0317104B1 publication Critical patent/BR0317104B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçõES FARMACêUTICAS DISPERSáVEIS". Fornece-se uma composição farmacêutica incluindo um veículo que compreende (a) um óleo anfipático dispersável em água e insolúvel em etanol, (b) cera microcristalina, e (c) um veículo não aquoso farmaceuticamente aceitável, e tendo uma substância antibacteriana, em uma quantidade eficaz do ponto de vista antibacteriano, estavelmente dispersa no veículo. A composição é adequada para administração de uma infusão intramamária em um animal produtor de leite para o tratamento e/ou prevenção da mastite ou de outras doenças do úbero, bem como para administração ótica para tratamento e/ou na prevenção de uma infecção do ouvido.
BRPI0317104A 2002-12-19 2003-12-11 composição farmacêutica dispersável estável compreendendo uma substância antibacteriana e artigo de fabricação contendo a referida composição BR0317104B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43498502P 2002-12-19 2002-12-19
US10/687,986 US7842791B2 (en) 2002-12-19 2003-10-17 Dispersible pharmaceutical compositions
PCT/US2003/039508 WO2004060345A2 (en) 2002-12-19 2003-12-11 Dispersible pharmaceutical compositions

Publications (2)

Publication Number Publication Date
BR0317104A true BR0317104A (pt) 2005-10-25
BR0317104B1 BR0317104B1 (pt) 2018-01-09

Family

ID=32717791

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0317104A BR0317104B1 (pt) 2002-12-19 2003-12-11 composição farmacêutica dispersável estável compreendendo uma substância antibacteriana e artigo de fabricação contendo a referida composição

Country Status (25)

Country Link
US (1) US7842791B2 (pt)
EP (1) EP1575618B1 (pt)
JP (1) JP3803683B2 (pt)
KR (1) KR100752836B1 (pt)
CN (1) CN100355457C (pt)
AR (1) AR042537A1 (pt)
AT (1) ATE336264T1 (pt)
AU (1) AU2003296947B2 (pt)
BR (1) BR0317104B1 (pt)
CA (1) CA2504065C (pt)
CY (1) CY1105202T1 (pt)
DE (1) DE60307677T2 (pt)
DK (1) DK1575618T3 (pt)
ES (1) ES2268496T3 (pt)
HK (1) HK1081457A1 (pt)
MX (1) MXPA05006739A (pt)
NO (1) NO20052306L (pt)
NZ (1) NZ540715A (pt)
PL (1) PL377518A1 (pt)
PT (1) PT1575618E (pt)
RU (1) RU2311201C2 (pt)
SI (1) SI1575618T1 (pt)
TW (1) TW200420299A (pt)
WO (1) WO2004060345A2 (pt)
ZA (1) ZA200504873B (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
EP1556009B2 (en) 2002-10-25 2021-07-21 Foamix Pharmaceuticals Ltd. Cosmetic and pharmaceutical foam
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US20040214753A1 (en) * 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
US20050004098A1 (en) * 2003-03-20 2005-01-06 Britten Nancy Jean Dispersible formulation of an anti-inflammatory agent
US20050009931A1 (en) * 2003-03-20 2005-01-13 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
EP1651210A1 (en) * 2003-07-31 2006-05-03 Pharmacia & Upjohn Company LLC Dispersible formulation of an anti-inflammatory agent
US20060046970A1 (en) * 2004-08-31 2006-03-02 Insite Vision Incorporated Topical otic compositions and methods of topical treatment of prevention of otic infections
US20090005448A1 (en) * 2005-01-19 2009-01-01 Nippon Zenyaku Kogyo Co., Ltd Injection for Mastitis
KR100748252B1 (ko) 2006-05-08 2007-08-10 주식회사 삼양애니팜 플로르페니콜 및 타이로신 함유 주사용 조성물
EP2059231A1 (en) * 2006-08-30 2009-05-20 Intervet International BV Pharmaceutical compositions comprising cefquinome
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
WO2008096918A1 (en) * 2007-02-09 2008-08-14 Kolon Industries, Inc Reactive antibioties and a method of preparing the same and antibacterial fiber treated thereby
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
EP2296632A4 (en) * 2008-07-14 2014-11-12 Otonomy Inc APOPTOSEMODULATING COMPOSITIONS WITH TAXED RELEASE AND METHOD FOR TREATING EAR OR DISEASES
US20120087872A1 (en) 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
CN101804058A (zh) * 2010-04-22 2010-08-18 中国农业科学院兰州畜牧与兽药研究所 一种用于防治奶牛干奶期***炎的药物及制备方法
SG10201508982TA (en) * 2010-11-01 2015-12-30 Melinta Therapeutics Inc Pharmaceutical compositions
CN102058612B (zh) * 2011-01-06 2012-07-04 河南亚卫动物药业有限公司 一种兽用复方乳浊液及其制备方法
WO2013056079A1 (en) * 2011-10-13 2013-04-18 The Johns Hopkins University High affinity beta lactamase inhibitors
KR101352867B1 (ko) 2011-11-07 2014-01-21 주식회사 한동 동물용 복합항생제 조성물
PL2819699T3 (pl) 2012-02-27 2019-11-29 Bayer New Zealand Ltd Kompozycje o kontrolowanym uwalnianiu i sposoby ich zastosowania
CN103479660A (zh) * 2012-06-14 2014-01-01 符波 一种治疗奶牛临床型***炎的***注入剂及其制备方法
KR101458611B1 (ko) * 2012-08-02 2014-11-11 주식회사 한동 동물용 복합항생제 조성물
CN105492005A (zh) * 2013-02-08 2016-04-13 罗达制药有限公司 治疗包括***炎的微生物感染的方法
MX2020012139A (es) 2016-09-08 2021-01-29 Vyne Pharmaceuticals Inc Composiciones y metodos para tratar rosacea y acne.
CN106265595B (zh) * 2016-09-29 2019-05-03 甘肃瑞和祥生物科技有限公司 一种肠溶吉他霉素缓释微球及其制备方法
CN106361707B (zh) * 2016-09-30 2019-02-26 广东温氏大华农生物科技有限公司 一种酒石酸泰万菌素颗粒制剂及其制备方法
CN109045044B (zh) * 2018-07-04 2020-11-17 佛山市南海东方澳龙制药有限公司 一种复方药剂及其制备方法、用途
BR112021017536A2 (pt) * 2019-03-06 2021-11-09 Zoetis Services Llc Composições de suspensão injetáveis prontas para uso e uso das mesmas para tratar uma infecção bacteriana em um animal
CN112716898A (zh) * 2021-02-22 2021-04-30 青岛康地恩动物药业有限公司 一种替米考星自乳化口服制剂及其制备方法

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA670254A (en) 1963-09-10 E. Gouge Hardin Mastitis composition
US3144386A (en) * 1958-05-09 1964-08-11 Merck & Co Inc Mastitis aerosol foam
GB980282A (en) 1960-03-24 1965-01-13 Philips Roxane Antibiotic mastitis composition
US3135658A (en) * 1961-10-10 1964-06-02 Merck & Co Inc Non-aqueous oleaginous aerosol foam therapy of bovine mastitis
US3347743A (en) * 1964-01-03 1967-10-17 Richardson Merrell Inc Method of treating bovine masititis
GB1089523A (en) 1964-06-25 1967-11-01 Astra Hewlett Ltd Improvements in or relating to veterinary compositions for treating mastitis
GB1181527A (en) 1966-09-21 1970-02-18 Douglas Gabriel Parizeau Composition and Method for Treating Mastitis with Therapeutic Agents.
US3531481A (en) * 1969-04-21 1970-09-29 Lilly Co Eli Method for manufacture of crystalline cephalosporin
US3636194A (en) * 1969-10-23 1972-01-18 Douglas G Parizeau Composition and method for treating mastitis with therapeutic agents
DE2063896A1 (de) 1970-12-28 1972-07-20 Dynamit Nobel Ag, 5210 Troisdorf Salbengrundlagen auf der Basis von Triglyceriden gesättigter mittelkettiger Fettsäuren und Verfahren zu deren Herstellung
CA1052697A (en) 1974-03-29 1979-04-17 Upjohn Company (The) Composition for treating mastitis in animals
DK154939C (da) * 1974-12-19 1989-06-12 Takeda Chemical Industries Ltd Analogifremgangsmaade til fremstilling af thiazolylacetamido-cephemforbindelser eller farmaceutisk acceptable salte eller estere deraf
US4006138A (en) * 1975-04-11 1977-02-01 Eli Lilly And Company Crystalline form of sodium O-formylcefamandole
US4011312A (en) * 1975-06-25 1977-03-08 American Home Products Corporation Prolonged release drug form for the treatment of bovine mastitis
GB1547164A (en) * 1975-08-14 1979-06-06 Beecham Group Ltd Veterinary compositions
GB1589917A (en) 1976-11-27 1981-05-20 Beecham Group Ltd Pharmaceutical composition containing a clavulanic acid derivative
DE2760123C2 (de) * 1976-01-23 1986-04-30 Roussel-Uclaf, Paris 7-Aminothiazolyl-syn-oxyiminoacetamidocephalosporansäuren, ihre Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
GB1532682A (en) * 1976-04-27 1978-11-22 Bristol Myers Co Process for the preparation of cephadroxil
US4172138A (en) * 1977-03-23 1979-10-23 Rhodes Russell E Method and composition of matter for the treatment of dry cows for mastitis
US4104470A (en) * 1977-06-03 1978-08-01 Eli Lilly And Company Crystallization process for cefazolin sodium
IT1162442B (it) * 1978-01-17 1987-04-01 Glaxo Group Ltd Procedimento per preparare il sale sodico di cefurossima in forma cristallina
FI65914C (fi) * 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
US4299501A (en) * 1979-08-10 1981-11-10 Ortho Pharmaceutical Corporation Continuous process for the preparation of semisolid dispersions
FR2479229B1 (fr) * 1980-03-26 1986-01-17 Clin Midy Nouveaux derives des cephalosporines, leur procede de preparation et les medicaments utilisables comme antibiotiques qui contiennent lesdits derives
NL8002636A (nl) * 1980-05-08 1981-12-01 Gist Brocades Nv Solvaat van amoxicilline, werkwijze ter bereiding hiervan en werkwijze ter bereiding van injectiepreparaten uit dit solvaat.
EP0058015A3 (en) 1981-02-05 1982-08-25 Beecham Group Plc Treatment of infections
JPS57134482A (en) * 1981-02-13 1982-08-19 Dainippon Pharmaceut Co Ltd 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8- naphthyridine-3-carboxylic acid-3/2 hydrate and its preparation
US4400503A (en) * 1981-10-30 1983-08-23 Eli Lilly And Company Purification of syn-7-[[(2-amino-4-thiazolyl)(methoxyimino) acetyl]amino]-3-methyl-3-cephem-4-carboxylic acid
JPS58198489A (ja) * 1982-05-14 1983-11-18 Meiji Seika Kaisha Ltd ７β−（２Ｄ−２−アミノ−２−カルボキシエチルチオアセトアミド）−７α−メトキシ−３−（１−メチル−１Ｈ−テトラゾ−ル−５−イル）−チオメチル−３−セフエム−４−カルボン酸ナトリウム塩の七水和物及びその製造方法
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
US4474780A (en) * 1983-07-22 1984-10-02 Eli Lilly And Company Crystalline cephalosporin
DE3313818A1 (de) * 1983-04-16 1984-10-18 Hoechst Ag, 6230 Frankfurt Neue kristallmodifikation von ceftazidim
JPS60120886A (ja) * 1983-12-02 1985-06-28 Takeda Chem Ind Ltd セフェムカルボン酸のナトリウム塩の結晶
US4616080A (en) * 1984-07-02 1986-10-07 Eli Lilly And Company Simplified process of forming crystalline ceftazidime pentahydrate
EP0170623B1 (en) * 1984-08-02 1990-11-28 Sandoz Ag Novel pharmaceutical use of (nva)2-cyclosporine
US4902683A (en) * 1984-10-25 1990-02-20 The Upjohn Company Crystalline cephalosporin hydrohalide salts
ATE138664T1 (de) * 1985-08-12 1996-06-15 Upjohn Co Umwandlung des cephalosporin-hydrohalid-salzes zu einem alkalimetallsalz
IT1190445B (it) 1985-11-08 1988-02-16 Fatro Spa Composizioni veterinarie a base di agenti antimicrobici e loro impiego
HU194493B (en) * 1985-11-27 1988-02-29 Chinoin Gyogyszer Es Vegyeszet Process for preparing primycin-containing colloidal basic gel and compositions comprising the same
GB8531609D0 (en) 1985-12-23 1986-02-05 Beecham Group Plc Compounds
US5017380A (en) * 1986-07-02 1991-05-21 Shionogi & Co., Ltd. Gelatin hard capsule containing crystalline hydrate of oral cephalosporin
NZ220764A (en) * 1986-07-02 1989-09-27 Shionogi & Co Crystalline form of 7beta((z)-2-(2-aminothiazol-4-yl)-4- carboxybut-2-enoylamino)-3-cephem-4-carboxylic acid and pharmaceutical compositions
CH668187A5 (de) * 1986-08-07 1988-12-15 Ciba Geigy Ag Therapeutisches system mit systemischer wirkung.
GB8621484D0 (en) 1986-09-05 1986-10-15 Norbrook Lab Ltd Intramammary infusion
US4723112A (en) 1986-09-19 1988-02-02 Tektronix, Inc. Level shift circuit for differential signals
GB8629481D0 (en) 1986-12-10 1987-01-21 Beecham Group Plc Veterinary treatment
IT1214587B (it) * 1986-12-23 1990-01-18 Giovanni Bonfanti Metodo per la produzione diprodotti cristallini puri.
ATE76874T1 (de) 1987-02-02 1992-06-15 Lilly Co Eli Verfahren zur herstellung von ceftazidimepentahydrat.
US5079007A (en) * 1987-07-29 1992-01-07 The Upjohn Company Controlled release of antibiotic salts from an implant
US4898938A (en) * 1987-08-03 1990-02-06 Rifar S.R.L. Method for preparing crystalline cefadroxil monohydrate
US4877782A (en) * 1988-02-16 1989-10-31 The Upjohn Company Zinc ceftiofur complexes
FR2635463A1 (fr) 1988-08-19 1990-02-23 Veprol Composition pharmaceutique comportant un principe actif peu soluble dans l'eau et au moins un glyceride gelifie par au moins un polymere cellulosique
ES2052016T3 (es) * 1988-09-29 1994-07-01 Shiseido Co Ltd Composicion emulsionada.
DE3919259A1 (de) 1989-06-13 1990-12-20 Hoechst Ag Kristalline cephem-saeureadditionssalze und verfahren zu ihrer herstellung
US5143137A (en) * 1990-03-08 1992-09-01 Rite-Hite Corporation Overlapping seal for insulated folding door
US5284662A (en) * 1990-10-01 1994-02-08 Ciba-Geigy Corp. Oral osmotic system for slightly soluble active agents
US5342612A (en) * 1991-12-20 1994-08-30 American Cyanamid Company Compositions for the treatment of mammalian diseases
US5314685A (en) * 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
ES2079994B1 (es) 1992-10-07 1996-08-01 Cusi Lab Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
WO1995031180A1 (en) 1992-12-08 1995-11-23 Bimeda Research And Development Limited A veterinary composition
GB2273443B (en) 1992-12-08 1997-01-08 Bimeda Res Dev Ltd Veterinary composition for the treatment of mastitis
DK0690864T3 (da) * 1993-03-12 2001-09-17 Upjohn Co Krystallinsk ceftiofur på fri syreform
DE69435141D1 (de) 1993-07-19 2008-10-30 Angiotech Pharm Inc Anti-angiogene Mittel und Verfahren zu deren Verwendung
US6054136A (en) * 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
DE4340781C3 (de) * 1993-11-30 2000-01-27 Novartis Ag Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
US5635159A (en) * 1994-08-26 1997-06-03 Abbott Laboratories Aerosol drug formulations containing polyglycolyzed glycerides
MX9701731A (es) * 1995-06-06 1997-10-31 Bayer Ag Composiciones anti-bacterianas oticas, no-irritantes, no-sensibles y no-toxicas para el oido.
US5736151A (en) * 1996-12-09 1998-04-07 Pharmacia & Upjohn Company Antibiotic oil suspensions
JP2002513750A (ja) 1998-05-07 2002-05-14 エラン コーポレーシヨン ピーエルシー 溶媒／助溶剤を含まないマイクロエマルジョン及びエマルジョンプレ濃縮物のドラッグデリバリーシステム
AR018376A1 (es) 1998-05-26 2001-11-14 Novartis Ag Composiciones farmaceuticas que se pueden dispersar de una manera espontanea y el uso de las mismas para la manufactura de un medicamento
ES2215277T3 (es) 1998-08-18 2004-10-01 Panacea Biotec Limited Composicion de ciclosporina que comprende un vehiculo hidrofilo.
US6440964B1 (en) * 1998-09-30 2002-08-27 Alcon Manufacturing, Ltd. Compositions and methods for treating ophthalmic and otic infections
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US6395746B1 (en) * 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
AR020660A1 (es) * 1998-09-30 2002-05-22 Alcon Lab Inc Composiciones antibioticas para el tratamiento de ojos, oidos y nariz
IT1303793B1 (it) 1998-11-27 2001-02-23 Promefarm S R L "composizione farmaceutica comprendente un composto organico donatoredi ossido nitrico (no)"
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds
GB9922710D0 (en) * 1999-09-24 1999-11-24 Bayer Ag Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatatives for the treatment of multiple sclerosis
US20010049366A1 (en) * 2000-02-09 2001-12-06 Alcon Universal Ltd. Topical solution formulations containing an antibiotic and a corticosteroid
WO2001089495A2 (en) 2000-05-19 2001-11-29 Alcon Laboratories, Inc. Antibiotic compositions containing quinolone derivatives for treatment of the eye, ear and nose
NZ524694A (en) * 2000-09-12 2005-05-27 Upjohn Co Pharmaceutical composition having modified carrier

Also Published As

Publication number Publication date
KR100752836B1 (ko) 2007-08-29
DE60307677D1 (de) 2006-09-28
CN1720065A (zh) 2006-01-11
US20040214752A1 (en) 2004-10-28
ES2268496T3 (es) 2007-03-16
NO20052306L (no) 2005-07-19
DE60307677T2 (de) 2007-08-16
AU2003296947A1 (en) 2004-07-29
DK1575618T3 (da) 2006-11-13
AU2003296947B2 (en) 2009-02-19
SI1575618T1 (sl) 2006-12-31
BR0317104B1 (pt) 2018-01-09
CN100355457C (zh) 2007-12-19
EP1575618A2 (en) 2005-09-21
US7842791B2 (en) 2010-11-30
EP1575618B1 (en) 2006-08-16
RU2311201C2 (ru) 2007-11-27
HK1081457A1 (en) 2006-05-19
MXPA05006739A (es) 2005-09-08
TW200420299A (en) 2004-10-16
WO2004060345A2 (en) 2004-07-22
PL377518A1 (pl) 2006-02-06
CA2504065C (en) 2010-06-29
ATE336264T1 (de) 2006-09-15
ZA200504873B (en) 2006-04-26
NZ540715A (en) 2008-03-28
PT1575618E (pt) 2006-11-30
NO20052306D0 (no) 2005-05-11
RU2005119159A (ru) 2006-01-20
JP3803683B2 (ja) 2006-08-02
JP2006514955A (ja) 2006-05-18
KR20050084416A (ko) 2005-08-26
CY1105202T1 (el) 2010-03-03
WO2004060345A3 (en) 2004-10-07
AR042537A1 (es) 2005-06-22
CA2504065A1 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
BR0317104A (pt) Composições farmacêuticas dispersáveis
BRPI0408559A (pt) composições farmacêuticas dispersìveis para o tratamento de mastite e distúrbios óticos
PT1079806E (pt) Preparacoes para a aplicacao de anti-inflamatorios, especialmente, agentes anti-septicos e/ou agentes de promocao da cura de feridas, no tracto respiratorio superior e/ou no ouvido
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
ATE418324T1 (de) Mucoadhäsive xyloglucan-haltige formulierung für medizinprodukte und pharmazeutische darreichungsformen
DOP2000000114A (es) Oxazolidinonas substituidas y su uso
BRPI9908182B8 (pt) composições de proteína de matriz para cura de feridas
BR0205722A (pt) Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor
MXPA04011612A (es) Uso oftalmologico de roflumilasto para el tratamiento de enfermedades del ojo.
ATE200733T1 (de) Pharmazeutische zubereitungen, die fluoxetin enthalten
DE69931159D1 (de) Antimikrobielle zusammensetzungen enthaltend taurolidin, zitronensäure und natriumzitrat
BR0111034A (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou doenças inflamatórias, para o tratamento e/ou profilaxia de osteoporose e para o tratamento de doenças relacionadas à aids
PT782448E (pt) Formulacoes oticas antibacterianas nao ototoxicas nao sensibilizantes nao irritantes
US20140348775A1 (en) Wound treatment drug for external use
BR0313148A (pt) Formulações de liberação controlada compreendendo lamotrigina
HK1073252A1 (en) Use of antiseptics in the manufacture of a pharmaceutical preparation for the prevention or treatment of inflammations in the interior of the human body
AU2002231889A1 (en) Halogenated composition, method for preparing same and uses thereof
DK1228758T3 (da) Anvendelse af sulfodehydroabietinsyre til behandling af inflammatorisk tarmsygdom
DE60320034D1 (de) Behandlung von mastitis mit einer kombination aus prednisolon und cephalosporin
DK1343472T3 (da) Thixotropisk næsespray
DE60043886D1 (de) Formulierungen mit povidon-iod zur behandlung von wunden
ATE283060T1 (de) Verwendung einer pollenextrakt-haltigen verbindung zur behandlung hormon-assoziierter erkrankungen
BR0110845A (pt) Derivados de dissulfeto de anilina para o tratamento de doenças alérgicas
BRPI0410576A (pt) composto quìmico, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método para o tratamento, prevenção ou alìvio de uma doença ou um distúrbio ou condição de um corpo de animal vivo
BRPI0411524A (pt) formulação farmacêutica de amoxicilina e clavulanato, uso de carboximetilcelulose de sódio, e, método de tratar infecção bacteriana em pacientes pediátricos

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: PHARMACIA AND UPJOHN COMPANY LLC (US)

Free format text: ALTERADO DE: PHARMACIA AND UPJOHN COMPANY

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 47/44; A61K 31/545; A61P 31/00

Ipc: A61K 47/44 (2011.01), A61K 31/545 (2011.01), A61P

B25A Requested transfer of rights approved

Owner name: PAH PANDU LLC (US)

B25D Requested change of name of applicant approved

Owner name: ZOETIS PANDU LLC (US)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM OS ARTIGOS 8O, 13, 24 E 25 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: ZOETIS SERVICES LLC (US)

B25G Requested change of headquarter approved

Owner name: ZOETIS SERVICES LLC (US)

B25K Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication

Owner name: ZOETIS SERVICES LLC (US)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]